An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Trial Profile

An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms MOA
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Jun 2016 Planned End Date changed from 1 Jun 2014 to 1 Jun 2017.
    • 17 Sep 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top